酒精成和阿尔茨海默病:一个分子碰撞过程
Jia-Sheng Chang1, He-Zhou Huang2, Mei Yuan1
1The Second Affiliated Hospital, Department of Neurology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Translational psychiatry
|October 17, 2025
概括
慢性饮酒会通过加速神经退行,使阿尔茨海默病 (AD) 恶化. 策略包括神经保护,炎症控制和生活方式的改变,以减轻风险和减缓进展.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 老年学是一门学科.
背景情况:
- 慢性饮酒是阿尔茨海默病 (AD) 的一个日益增长的危险因素.
- 过度饮酒会通过神经退行导致认知能力下降.
- 滥用酒精会通过蛋白质清除受损,神经递质失衡,炎症和氧化应激加剧AD病理.
研究的目的:
- 探索慢性饮酒与阿尔茨海默病之间的联系.
- 概述酒精加速神经退行的生物机制.
- 审查目前和新兴的治疗策略,以减轻酒精诱导的AD风险.
主要方法:
- 对有关酒精消费和阿尔茨海默病的研究的文献综述.
- 分析过度饮酒影响的生物途径.
- 综合关于治疗干预和生活方式改变的信息.
主要成果:
- 酒精消费加速神经退行,损害有毒蛋白质清除,破坏神经递质平衡.
- 过度饮酒会增加大脑炎症和氧化应激,降低神经元的弹性.
- 药理学 (神经保护药物,抗炎药物) 和生活方式干预 (禁欲,认知训练,营养) 都显示出潜力.
结论:
- 慢性饮酒显著增加了阿尔茨海默病的风险和进展.
- 缓解酒精诱导的神经毒性需要一个多方面的方法,结合医疗治疗和生活方式调整.
- 个性化医疗和先进的药物输送系统对于未来的治疗疗效至关重要.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
CNS Depressants: Alcohol and Nicotine
1.0K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.0K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Drug Abuse and Addiction: Pharmacological Phenomena
1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K


